Small-Cap Earnings Spotlight: Lexicon and Ituran Navigate Q4 Inflection Points
Investors are bracing for Q4 2025 results from Lexicon Pharmaceuticals and Ituran Location, two small-cap players facing critical operational milestones. While Lexicon seeks to prove the commercial viability of its heart failure treatment, Ituran aims to capitalize on expanding telematics demand in emerging markets.